https://www.selleckchem.com/products/myci975.html
Kaplan-Meier analyses revealed that the primary endpoint was not significantly different between the treatment groups for the less then 131 mg/dL group, however, it was significantly lower in patients treated with pitavastatin + ezetimibe in the ≥ 131 mg/dL group (Hazard ratio = 0.72, 95% confidence interval = 0.56-0.91, P = 0.007, P value for interaction = 0.012). Statin-naïve ACS patients with baseline LDL-C less then 131 mg/dL did not clinically benefit from pitavastatin + ezetimibe, while patients with baseline LDL-C ≥ 131 mg/dL
Curtir
Comentario
Compartilhar
